China’s NMPA approves Henlius’ oesophageal cancer therapy

China has granted approval for Henlius Biotech’s Hansizhuang for patients with oesophageal squamous cell carcinoma (ESCC).

Sep 25, 2023 - 20:00

China’s NMPA approves Henlius’ oesophageal cancer therapy

China has granted approval for Henlius Biotech’s Hansizhuang for patients with oesophageal squamous cell carcinoma (ESCC).

Read the original article

Tags:

Previous Article

Novartis eyes first-line status for its radionucleotide therapy Lutathera

Valneva receives JE vaccine supply contract from US DoD

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Rezvilutamide by Jiangsu Hengrui Medicine for Liver Fai...

Jun 5, 2023

Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro

Pfizer’s twice daily pill for obesity hopes to rival We...

Oct 26, 2023

OncoVerity eyes cusatuzumab development in AML after licensing rights

OncoVerity eyes cusatuzumab development in AML after li...

Mar 29, 2023